New directions in Parkinson’s research and treatment

Author： Napolitano A.   Pezzella A.   Misuraca G.   Prota G.  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.8, Iss.10, 1998-10, pp. : 1251-1268

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ropinirole in the treatment of Parkinson’s disease

By Zesiewicz T.A.   Hauser R.A.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 697-710

Informa Healthcare

Access to resources Recommend Favorite

Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease

By  

Current Medicinal Chemistry, Vol. 23, Iss. 4, 2016-02 ,pp. : 346-359

Bentham Science Publishers

Access to resources Recommend Favorite

Non-dopaminergic drug treatment of Parkinson’s disease

By Müller T.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 4, 2001-04 ,pp. : 557-572

Informa Healthcare

Access to resources Recommend Favorite

Emerging Therapies in the Pharmacological Treatment of Parkinson’s Disease

By Korczyn A.D.   Nussbaum M.  

Drugs, Vol. 62, Iss. 5, 2002-01 ,pp. : 775-786

Adis International

Access to resources Recommend Favorite

Treatment of Psychosis in Parkinson’s Disease: Safety Considerations

By Fernandez H.H.   Trieschmann M.E.   Friedman J.H.  

Drug Safety, Vol. 26, Iss. 9, 2003-01 ,pp. : 643-659

Adis International

Access to resources Recommend Favorite